{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:16:37Z","timestamp":1793931397268,"version":"4.8.0"},"reference-count":28,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Tumor necrosis factor (TNF) antagonists and vedolizumab are the most commonly used advanced therapies for management of moderate-to-severe ulcerative colitis (UC). There are limited data evaluating long-term outcomes with a TNF antagonist\u2013first vs vedolizumab-first treatment strategy.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To compare long-term clinical outcomes among biologic-naive patients with UC initiating infliximab or adalimumab vs vedolizumab as first-line advanced therapy.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This Swedish nationwide population-based cohort study used linked health registers. Biologic-naive patients with UC who initiated infliximab, adalimumab, or vedolizumab between January 1, 2015, and June 30, 2021, were included and followed up until June 30, 2023, for a median of 4.3 to 5.4 years. Data analysis was conducted from April to September 2025.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Initiation of a TNF antagonist (ie, infliximab or adalimumab) or vedolizumab as first-line advanced therapy.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was the incidence rate of all-cause hospitalizations (including recurrent events). Secondary outcomes included incidence rates of colectomy, corticosteroid dispensations, advanced therapy switching, and proportion of quarters spent in corticosteroid-free disease stability (defined as no oral corticosteroid dispensation, no initiation of a new advanced therapy or immunomodulator, and no hospitalization or colectomy within a 3-month period). Groups were balanced using inverse probability of treatment weighting (IPTW) accounting for disease characteristics, health care utilization, comorbidities, and medication use.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Overall, 3263 patients (1393 infliximab, 1583 adalimumab, and 287 vedolizumab initiators) were included. After IPTW, there were with 1385 infliximab initiators (mean [SD] age, 38 [18] years; 43% female) compared with 320 vedolizumab initiators (mean [SD] age, 36 [19] years; 35% female) and 1575 adalimumab initiators (mean [SD] age, 41 [16] years; 48% female) compared with 318 vedolizumab initiators (mean [SD] age, 38 [19] years; 43% female). All-cause hospitalization did not differ significantly between infliximab and vedolizumab initiators (incidence rate ratio [IRR], 1.14 [95% CI, 0.91-1.43]); however, infliximab initiators spent a significantly lower proportion of time in corticosteroid-free disease stability over 5 years than vedolizumab initiators (60% vs 67% of quarters; risk ratio [RR], 0.88 [95% CI, 0.82-0.94]). Similarly, all-cause hospitalization did not differ significantly between adalimumab and vedolizumab initiators (IRR, 1.08 [95% CI, 0.86-1.35]), although adalimumab initiators had greater therapy switching (IRR, 1.21 [95% CI, 1.02-1.43]) and less time in corticosteroid-free stability (67% vs 70% of quarters; RR, 0.92 [95% CI, 0.87-0.98]) than vedolizumab initiators. Results were broadly consistent in 1:1 propensity score\u2013matched sensitivity analyses.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study of biologic-naive patients with UC initiating advanced therapy, the burden of hospitalization did not differ significantly between patients receiving vedolizumab and those receiving a TNF agonist; however, a vedolizumab-first strategy was associated with a greater proportion of time spent in corticosteroid-free disease stability over 5 years than a TNF antagonist\u2013first strategy. These findings may inform first-line treatment selection in UC.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.36165","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:30:41Z","timestamp":1790350241000},"page":"e2636165","source":"Crossref","is-referenced-by-count":1,"title":["Vedolizumab vs TNF Antagonists and Long-Term Outcomes in Ulcerative Colitis"],"prefix":"10.1001","volume":"9","author":[{"given":"Siddharth","family":"Singh","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic Arizona, Scottsdale"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"S\u00f6derling","sequence":"additional","affiliation":[{"name":"Division of Clinical Epidemiology, Department of Medicine, Karolinska Institutet, Solna, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Forss","sequence":"additional","affiliation":[{"name":"Division of Clinical Epidemiology, Department of Medicine, Karolinska Institutet, Solna, Sweden"},{"name":"Department of Gastroenterology, Centre for Digestive Health, Dermatovenereology and Rheumatology, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Rask-Andersen","sequence":"additional","affiliation":[{"name":"Division of Clinical Epidemiology, Department of Medicine, Karolinska Institutet, Solna, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Halfvarson","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Faculty of Medicine and Health, \u00d6rebro University, \u00d6rebro, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c5sa H.","family":"Everhov","sequence":"additional","affiliation":[{"name":"Division of Clinical Epidemiology, Department of Medicine, Karolinska Institutet, Solna, Sweden"},{"name":"Department of Clinical Science and Education, S\u00f6dersjukhuset, Karolinska Institutet, Stockholm, Sweden"},{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Solna, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas F.","family":"Ludvigsson","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Solna, Sweden"},{"name":"Department of Pediatrics, \u00d6rebro University Hospital, \u00d6rebro, Sweden"},{"name":"Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Ol\u00e9n","sequence":"additional","affiliation":[{"name":"Division of Clinical Epidemiology, Department of Medicine, Karolinska Institutet, Solna, Sweden"},{"name":"Department of Pediatric Gastroenterology and Nutrition, Sachs Children and Youth Hospital, S\u00f6dersjukhuset, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"SWIBREG study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malin","family":"Olsson","sequence":"additional","affiliation":[{"name":"for the SWIBREG study group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e4r","family":"Myrelid","sequence":"additional","affiliation":[{"name":"for the SWIBREG study group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Hjortswang","sequence":"additional","affiliation":[{"name":"for the SWIBREG study group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Bengtsson","sequence":"additional","affiliation":[{"name":"for the SWIBREG study group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Strid","sequence":"additional","affiliation":[{"name":"for the SWIBREG study group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Andersson","sequence":"additional","affiliation":[{"name":"for the SWIBREG study group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"J\u00e4ghult","sequence":"additional","affiliation":[{"name":"for the SWIBREG study group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Nordenvall","sequence":"additional","affiliation":[{"name":"for the SWIBREG study group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Hedin","sequence":"additional","affiliation":[{"name":"for the SWIBREG study group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Rejler","sequence":"additional","affiliation":[{"name":"for the SWIBREG study group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olof","family":"Grip","sequence":"additional","affiliation":[{"name":"for the SWIBREG study group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrika L","family":"Fagerberg","sequence":"additional","affiliation":[{"name":"for the SWIBREG study group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"M\u00e5rild","sequence":"additional","affiliation":[{"name":"for the SWIBREG study group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Hreinsson","sequence":"additional","affiliation":[{"name":"for the SWIBREG study group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pontus","family":"Karling","sequence":"additional","affiliation":[{"name":"for the SWIBREG study group"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"issue":"3","key":"zoi260975r1","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.cgh.2024.06.050","article-title":"Modern advanced therapies for inflammatory bowel diseases: practical considerations and positioning.","volume":"23","author":"Fudman","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"zoi260975r2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaf186","article-title":"Trends in utilization of advanced therapies in patients with inflammatory bowel diseases in the USA, 2021-2025.","volume":"19","author":"Singh","year":"2025","journal-title":"J Crohns Colitis"},{"issue":"10","key":"zoi260975r3","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1093\/ecco-jcc\/jjab058","article-title":"Vedolizumab and anti-tumour necrosis factor a real-world outcomes in biologic-na\u00efve inflammatory bowel disease patients: results from the EVOLVE study.","volume":"15","author":"Bressler","year":"2021","journal-title":"J Crohns Colitis"},{"key":"zoi260975r4","doi-asserted-by":"publisher","journal-title":"Clin Gastroenterol Hepatol","DOI":"10.1016\/j.cgh.2020.10.003"},{"issue":"4","key":"zoi260975r5","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/apt.18441","article-title":"Long-term outcomes of an infliximab-first versus vedolizumab-first treatment strategy in biologic-na\u00efve patients with ulcerative colitis.","volume":"61","author":"Haynesworth","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"issue":"13","key":"zoi260975r6","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","article-title":"Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis.","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"zoi260975r7","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1016\/j.cgh.2024.12.007","article-title":"Differential efficacy of advanced therapies in inducing remission in ulcerative colitis based on prior exposure to TNF antagonists.","volume":"23","author":"Lee","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"zoi260975r8","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s10654-009-9350-y","article-title":"The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research.","volume":"24","author":"Ludvigsson","year":"2009","journal-title":"Eur J Epidemiol"},{"issue":"5","key":"zoi260975r9","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s10654-025-01226-9","article-title":"The healthcare system in Sweden.","volume":"40","author":"Ludvigsson","year":"2025","journal-title":"Eur J Epidemiol"},{"issue":"9","key":"zoi260975r10","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1080\/00365521.2019.1660799","article-title":"Swedish Inflammatory Bowel Disease Register (SWIBREG)\u2014 a nationwide quality register.","volume":"54","author":"Ludvigsson","year":"2019","journal-title":"Scand J Gastroenterol"},{"issue":"3","key":"zoi260975r11","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s10654-025-01221-0","article-title":"Diagnostic accuracy in the Swedish national patient register: a review including diagnoses in the outpatient register.","volume":"40","author":"Everhov","year":"2025","journal-title":"Eur J Epidemiol"},{"key":"zoi260975r12","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1186\/1471-2458-11-450","article-title":"External review and validation of the Swedish national inpatient register.","volume":"11","author":"Ludvigsson","year":"2011","journal-title":"BMC Public Health"},{"issue":"4","key":"zoi260975r13","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1080\/00365521.2021.1884894","article-title":"Capturing biologic treatment for IBD in the Swedish Prescribed Drug Register and the Swedish National Patient Register\u2014a validation study.","volume":"56","author":"Br\u00f6ms","year":"2021","journal-title":"Scand J Gastroenterol"},{"issue":"5","key":"zoi260975r14","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/bcpt.12613","article-title":"The first decade with the Swedish Prescribed Drug Register\u2014a systematic review of the output in the scientific literature.","volume":"119","author":"Wallerstedt","year":"2016","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"1","key":"zoi260975r15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1080\/02841860802247664","article-title":"The completeness of the Swedish Cancer Register: a sample survey for year 1998.","volume":"48","author":"Barlow","year":"2009","journal-title":"Acta Oncol"},{"key":"zoi260975r16","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2147\/CLEP.S499859","article-title":"Cohort update: ESPRESSO (Epidemiology Strengthened by Histopathology Reports in Sweden).","volume":"17","author":"Ludvigsson","year":"2025","journal-title":"Clin Epidemiol"},{"issue":"2","key":"zoi260975r17","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s10654-016-0117-y","article-title":"Registers of the Swedish total population and their use in medical research.","volume":"31","author":"Ludvigsson","year":"2016","journal-title":"Eur J Epidemiol"},{"issue":"2","key":"zoi260975r18","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1080\/00365521.2016.1246605","article-title":"Validating inflammatory bowel disease (IBD) in the Swedish National Patient Register and the Swedish Quality Register for IBD (SWIBREG).","volume":"52","author":"Jakobsson","year":"2017","journal-title":"Scand J Gastroenterol"},{"key":"zoi260975r19","doi-asserted-by":"publisher","first-page":"591","DOI":"10.2147\/CLEP.S358031","article-title":"Identification of childhood-onset inflammatory bowel disease in Swedish healthcare registers: a validation study.","volume":"14","author":"Mouratidou","year":"2022","journal-title":"Clin Epidemiol"},{"issue":"11","key":"zoi260975r20","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/S2468-1253(20)30267-3","article-title":"Antibiotic use and the development of inflammatory bowel disease: a national case-control study in Sweden.","volume":"5","author":"Nguyen","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"12","key":"zoi260975r21","doi-asserted-by":"publisher","first-page":"2480","DOI":"10.14309\/ajg.0000000000002961","article-title":"Comparative Risk of serious infection with vedolizumab vs anti-tumor necrosis factor in inflammatory bowel disease: results from nationwide Swedish registers.","volume":"119","author":"Karlqvist","year":"2024","journal-title":"Am J Gastroenterol"},{"issue":"10132","key":"zoi260975r22","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1016\/S0140-6736(18)30668-8","article-title":"Development and validation of a Hospital Frailty Risk Score focusing on older people in acute care settings using electronic hospital records: an observational study.","volume":"391","author":"Gilbert","year":"2018","journal-title":"Lancet"},{"issue":"25","key":"zoi260975r23","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples.","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"issue":"4","key":"zoi260975r24","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1111\/apt.16193","article-title":"Drug survival of anti-TNF agents compared with vedolizumab as a second-line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers.","volume":"53","author":"Rundquist","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"zoi260975r25","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1093\/ecco-jcc\/jjad203","article-title":"Biologic therapy for inflammatory bowel disease: real-world comparative effectiveness and impact of drug sequencing in 13 222 patients within the UK IBD BioResource.","volume":"18","author":"Kapizioni","year":"2024","journal-title":"J Crohns Colitis"},{"key":"zoi260975r26","doi-asserted-by":"publisher","DOI":"10.1177\/17562848221080793","article-title":"Vedolizumab has longer persistence than infliximab as a first-line biological agent but not as a second-line biological agent in moderate-to-severe ulcerative colitis: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study.","volume":"15","author":"Pudipeddi","year":"2022","journal-title":"Ther Adv Gastroenterol"},{"key":"zoi260975r27","unstructured":"Svensk Gastroenterologisk F\u00f6rening. Vuxna med inflammatorisk tarmsjukdom (IBD)\u2014Nationellt v\u00e5rdprogram, 2023. April 28, 2023. Accessed August 24, 2026. https:\/\/svenskgastroenterologi.se\/kunskap\/nationellt-vardprogram-for-vuxna-med-inflammatorisk-tarmsjukdom-ibd-2023\/"},{"key":"zoi260975r28","unstructured":"L\u00e4kemedelsverket. L\u00e4kemedel vid inflammatorisk tarmsjukdom (IBD)\u2014behandlings-rekommendation. Updated June 7, 2022. Accessed August 24, 2026. https:\/\/www.lakemedelsverket.se\/sv\/behandling-och-forskrivning\/behandlingsrekommendationer\/sok-behandlingsrekommendationer\/lakemedel-vid-inflammatorisk-tarmsjukdom-ibd---behandlingsrekommendation"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2854494\/singh_2026_oi_260975_1790091784.87466.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:30:42Z","timestamp":1790350242000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2854494"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.36165","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]}}}